Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

2025 has come and gone. It was an interesting year and had its fair share of weird Vancouver stories. We’ve gone through some ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

The post Oracle Sinks Stocks-Market Analysis for December 17th, 2025 appeared first on Stock Target Advisor.

A new study published in the Journal of Autism and Developmental Disorders suggests that the ability to comprehend complex ...

The most important networking command in Linux might be ping. This command lets you check if a remote machine is responding ...

Peter Krull, director of Earth Equity Advisors, discusses why he's bullish on renewable energy and shares his top clean ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Former Speaker of the House Nancy Pelosi (D-Calif.) remains one of the most-followed members of Congress when it comes to ...